drugset / Trial / NCT02761460

The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia

NCT02761460

Phase 3 Unknown 338 enrolled wang shusen
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of PEG-rhG-CSF in preventing chemotherapy-induced neutropenia

Timeline

Start
2016-05-04
Primary completion
2018-04
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic 3 mg
Subject Pegfilgrastim Protein / enzyme biologic 6 mg

Indications